Practice

Dr Stephen Hanauer Gives Insight Into Growing US Adalimumab Market

October 29th 2023

By Skylar Jeremias

Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, reflects on data concerning the potential for adalimumab biosimilars to gain significant market share.

Commercial Biosimilar Coverage Is on the Rise, but Preferences Still Vary

October 28th 2023

By Skylar Jeremias

Article

A poster from AMCP Nexus quantifies trends in biosimilar coverage within Tufts Medical Center, finding that payer coverage of these products has increased but individual preferences among payers still vary.

Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake

October 24th 2023

By Skylar Jeremias

Article

Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.

Dr Stephen Hanauer Weighs In on Pharmacovigilence, Nonmedical Switching in Crohn Disease

October 22nd 2023

By Skylar Jeremias

Video

Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses why providers need to be wary when deciding whether patients with Crohn disease should switch from Humira (reference adalimumab) to an adalimumab biosimilar.

Review: Similar Safety Profiles of Biosimilar, Reference Pegfilgrastim in Clinical Studies

October 17th 2023

By Deana Ferreri, PhD

Article

Researchers of a literature review found similar safety profiles between biosimilar pegfilgrastim and its reference product (Neulasta) across several phase 1 and phase 3 clinical trials.

Varying Biosimilar Policies Create Uneven Market Sustainability Across Nations

October 12th 2023

By Skylar Jeremias

Article

An international comparative analysis found that the level of biosimilar market sustainability differs between countries, largely due to variances in biosimilar policies and years of experience managing a biosimilar market.

The Promise of Biosimilars Is Within Reach for Health Systems

October 7th 2023

By Jim Lichauer, PharmD, BCPS, FASHP

Article

A collaborative exercise with 16 health care organizations nets millions in savings.

Study: Multiple Switches Between Infliximab Products May Lead to Higher Rates of Treatment Discontinuation

September 26th 2023

By Skylar Jeremias

Article

Patients with inflammatory bowel disease who underwent a switch from reference infliximab to a biosimilar and then back to the originator were more likely to discontinue their treatment than patients who underwent a single switch from the originator to a biosimilar.

Patient Surveys Provide Insight Into Real-World Adalimumab Biosimilar Use in IBD

September 19th 2023

By Skylar Jeremias

Article

A study evaluating the real-world impact of treating patients with inflammatory bowel disease (IBD) with an adalimumab biosimilar found that providing patient questionnaires early can be useful for identifying those at a higher risk of treatment discontinuation.

Biologic Availability Contributes to Medicare Part B Drug Expenditure Growth

September 14th 2023

By Justina Petrullo

Article

Growing use of innovator biologics, including those with biosimilar competition, has led to increased Medicare Part B drug expenditures, with the trend unlikely to stop.